U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06942507) titled 'Zanubrutinib Combined With BR in the First-line Treatment of Waldenstrom's Macroglobulinemia' on April 17.
Brief Summary: Current retrospective studies have demonstrated that achieving deep remission following treatment for Waldenstrom macroglobulinemia (WM) correlates with prolonged survival. While the bortezomib-rituximab (BR) regimen or single-agent zanubrutinib are currently recommended as first-line therapies, neither achieves optimal deep remission. Additionally, prolonged zanubrutinib monotherapy may lead to cumulative adverse effects. Therefore, this study aims to evaluate the efficacy and safety of the bortezomib-rituximab...